ALX Oncology Holdings Inc. Sustainability Profile
ALX Oncology Holdings Inc., a prominent player in the biotechnology sector, is headquartered in the United States. Founded in 2015, the company focuses on developing innovative therapies for cancer treatment, particularly through its expertise in immune-oncology. ALX Oncology is renowned for its lead product candidate, ALX148, which is designed to enhance the immune response against tumours by targeting the CD47 pathway, a unique approach that sets it apart in the competitive landscape. With a strong operational presence in key regions, ALX Oncology has made significant strides in clinical development, achieving notable milestones that underscore its commitment to advancing cancer care. The company’s dedication to pioneering solutions positions it as a leader in the fight against cancer, making substantial contributions to the evolving landscape of oncology therapeutics.
DitchCarbon Score
How does ALX Oncology Holdings Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ALX Oncology Holdings Inc.'s score of 17 is lower than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
ALX Oncology Holdings Inc.'s reported carbon emissions
ALX Oncology Holdings Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and commitments suggests that ALX Oncology may still be in the early stages of developing a comprehensive climate strategy. As the industry increasingly prioritises sustainability, it will be essential for ALX Oncology to establish clear climate commitments and reduction initiatives to align with global standards and expectations.
How Carbon Intensive is ALX Oncology Holdings Inc.'s Industry?
How Carbon Intensive is ALX Oncology Holdings Inc.'s Location?
ALX Oncology Holdings Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
ALX Oncology Holdings Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
